Bone Marrow Mesenchymal Stem Cells (BMSC)-Derived miR-203-3p Ameliorates Acute Myocardial Infarction Through Activating Mammalian Target of Rapamycin (mTOR) Signaling Pathway

Cardiovascular disease is currently the number one threaten of human health, which is associated with a high morbidity and high mortality. It is suggested that miR-203-3p has a variety of biological activities such as anticoagulation. However, the role and mechanism of BMSC-derived miR-203-3p in acute myocardial infarction rats is unclear. The rat model of acute myocardial infarction (AMI) was established and then administrated with the mTOR inhibitor Rapamycin or si-miR-203-3p intervention. Hematoxylin-eosin (HE) staining detected pathologies of myocardial infarction, proteins expression was measured by Western blot and myocardial enzymes levels in rats were detected by ELISA. The rats in myocardial infarction model group showed severe myocardial damage, which were ameliorated after interventions of Rapamycin or si-miR-203-3p. The intervention of Rapamycin or si-miR-203-3p can inhibit the mTOR signaling pathway, decrease TNF-alpha and IL-6 secretion, and reduce the expression level of myocardial enzyme spectrum indicators. In conclusion, BMSC-derived miR-203-3p can inhibit mTOR-mediated inflammation and ameliorate myocardial infarction. Our study provides a basis and lays a scientific basis for the early drug development.